Teal Bio Raises $2.45M in Series A Funding

Teal Bio

Teal Bio, a Somerville MA-based medical device startup, raised $2.45M in Series A funding.

The round was led by Caligan Partners LP.

The company intends to use the funds to complete the development and regulatory approval of its reusable respiratory protection platform, which offers improvements in comfort, communication and conservation in personal protective equipment (PPE) for healthcare workers.

Led by Tony Casciano, CEO, a long-time Sanofi Genzyme Commercial Leader and former COO of AMAG pharma, Teal Bio provides reusable respiratory personal protective equipment. Its lead product, expected in 2022, is a reusable, patent-pending respirator platform that creates significantly less waste than traditional single-use masks, including N95s. The body, which is made of transparent medical-grade silicone, can be sanitized with alcohol wipes and reused. The replaceable filters—which are made of a substantially biodegradable blend that creates less waste and takes up less space than disposable N95 masks—snap in place and are replaced daily.

The company was founded by:

  • Dr. Robert Langer, Institute Professor at MIT and the most cited engineer in history;
  • Dr. Giovanni Traverso, Assistant Professor, Department of Mechanical Engineering at MIT, Division of Gastroenterology, Brigham and Women’s Hospital, Harvard Medical School;
  • Jason Troutner, former CTO of Cast21;
  • Adam Wentworth, Senior Clinical Engineer at Mayo Clinic and
  • Dr. James Byrne, Assistant Professor, Departments of Radiation Oncology and Biomedical Engineering, University of Iowa Health Care.

Teal Bio is based in Somerville, MA and operates out of Greentown Labs, a large climatetech incubator in North America.